Skip to main content

GSK plc 6-K, filed Oct 26, 2026

GSK plc (GSK)

6-K 2026-10-26 For: 2026-10-26
View Original
Added on October 26, 2026

About this 6-K

GSK plc filed this 6-K on October 26, 2026.

GSK’s ARTEMIS-011 trial found Ris-Rez reduced disease progression or death risk by 67% versus chemotherapy in relapsed osteosarcoma, with median progression-free survival of 5.5 months versus 1.4 months; Hansoh plans a China regulatory submission. AI summary